MediWound Ltd. (MDWD)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XFRA 
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
MediWound (MDWD) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.19 per share a year ago.
MediWound to launch Phase III trial for venous leg ulcers
MediWound , an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it was starting a Phase III trial for its treatment for venous leg ulcers.
MediWound (MDWD) Surges 8.5%: Is This an Indication of Further Gains?
MediWound (MDWD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
MediWound Ltd. (MDWD) Q3 2024 Earnings Call Transcript
MediWound Ltd. (NASDAQ:MDWD ) Q3 2024 Earnings Conference Call November 26, 2024 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - Executive Vice President, Strategy & Corporate Development Conference Call Participants Josh Jennings - Cowen Swayampakula Ramakanth - H.C.
MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates
MediWound (MDWD) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.24 per share a year ago.
MediWound Is A Healthy Investment
MediWound is a long-term buy opportunity with significant upside potential, driven by its innovative wound and lesion care products in a strong, growing industry. Despite current financial struggles, including increased losses and low margins, MediWound's revenue is expected to grow, and it garners support from government and industry investments. MDWD has shown strong momentum, nearly doubling in price YTD, and is backed by a healthy mix of institutional and private investors.
MediWound Ltd. (MDWD) Q2 2024 Earnings Call Transcript
MediWound Ltd. (NASDAQ:MDWD ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Gaia Shamis - IR, LifeSci Advisors Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - EVP of Strategy & Corporate Development Conference Call Participants Joshua Jennings - TD Cowen Swayampakula Ramakanth - HC Wainwright Michael Okunewitch - Maxim Group Operator Good day and welcome to MediWound's Second Quarter 2024 Earnings Call.
MediWound (MDWD) Reports Q2 Loss, Lags Revenue Estimates
MediWound (MDWD) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to earnings of $0.10 per share a year ago.
MediWound (MDWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
MediWound (MDWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can MediWound (MDWD) Climb 57.49% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 57.5% upside potential for MediWound (MDWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
MediWound Ltd. (MDWD) Q1 2024 Earnings Call Transcript
MediWound Ltd. (NASDAQ:MDWD ) Q1 2024 Earnings Conference Call May 29, 2024 8:30 AM ET Company Participants Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - Executive Vice President of Strategy, Corporate Development Daniel Ferry - Managing Director, LifeSci Advisors Conference Call Participants Josh Jennings - TD Cowen Francois Brisebois - Oppenheimer Swayampakula Ramakanth - HC Wainwright Michael Okunewitch - Maxim Group Operator Good day!
MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates
MediWound (MDWD) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.44 per share a year ago.
